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Abstract
Background: p53 is an important tumour suppressor with a known role in the later stages of
colorectal cancer, but its relevance to the early stages of neoplastic initiation remains somewhat
unclear. Although p53-dependent regulation of Wnt signalling activity is known to occur, the
importance of these regulatory mechanisms during the early stages of intestinal neoplasia has not
been demonstrated.
Methods: We have conditionally deleted the Adenomatous Polyposis coli gene (Apc) from the
adult murine intestine in wild type and p53 deficient environments and subsequently compared the
phenotype and transcriptome profiles in both genotypes.
Results: Expression of p53 was shown to be elevated following the conditional deletion of Apc in
the adult small intestine. Furthermore, p53 status was shown to impact on the transcription profile
observed following Apc loss. A number of key Wnt pathway components and targets were altered
in the p53 deficient environment. However, the aberrant phenotype observed following loss of Apc
(rapid nuclear localisation of β-catenin, increased levels of DNA damage, nuclear atypia, perturbed
cell death, proliferation, differentiation and migration) was not significantly altered by the absence
of p53.
Conclusion: p53 related feedback mechanisms regulating Wnt signalling activity are present in the
intestine, and become activated following loss of Apc. However, the physiological Wnt pathway
regulation by p53 appears to be overwhelmed by Apc loss and consequently the activity of these
regulatory mechanisms is not sufficient to modulate the immediate phenotypes seen following Apc
loss. Thus we are able to provide an explanation to the apparent contradiction that, despite having
a Wnt regulatory capacity, p53 loss is not associated with early lesion development.
Background
p53 is implicated in colorectal cancer as the final step of
multi-step carcinogenesis leading to carcinoma formation
[1]. However, p53 is also postulated to be involved as a
critical negative regulator of the Wnt signalling pathway,
arguing that it should also have a role in the tumour initi-
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Apcmin mouse has variably been reported to have no effect
or to modify adenoma formation [2-4]. Consequently
there is a need to further clarify the role of p53 function in
intestinal neoplasia.
Increased levels of β-catenin lead to increased transcrip-
tion of p14ARF (in human cells, p19ARF in murine cells)
which in turn inactivates Mdm2, allowing the activation
of p53 [5]. Active p53 is then able to down-regulate β-cat-
enin and a number of mechanisms for this feedback have
been proposed. These include a GSK3β independent
mechanism where the p53 target gene Siah1 interacts with
APC to promote the degradation of β-catenin [6]. A
GSK3β, CK1 dependent mechanism has also been pro-
posed, wherein, p53 activity mediates a faster mobiliza-
tion of Axin into the degradation complex. This results in
enhanced phosphorylation of β-catenin on key NH2-ter-
minal serines and consequently a heightened β-catenin
turnover [7]. In both of these scenarios there is, presuma-
bly, a requirement for active Apc in order to obtain inhi-
bition of Wnt signalling. However, p53 activity also affects
the expression of genes that are known regulators of Wnt
signalling e.g. p53 induces Dkk1 expression which is an
inhibitor of the Wnt signalling pathway acting upstream
of β-catenin [8], while Tcf-4 mRNA is down-regulated
after increased p53 expression [9]. Thus, in these scenarios
Wnt signalling could be inhibited independently to loss
of Apc.
Here, we report the consequence of p53 deficiency upon
the phenotypes observed immediately following Apc loss.
These data clarify the extent to which p53-dependent inhi-
bition of Wnt signalling can occur in this setting, and also
indicate whether p53 status is relevant to the tumour ini-
tiation process. To achieve this, we utilised mice bearing a
conditional Apc allele on either a wild type or p53 defi-
cient background [10,11] and determined if any p53
dependent feedback loops have a functional consequence
immediately following Apc loss. Thus we are able to
address whether p53 contributes to the early stages of
intestinal neoplasia or whether its role is restricted to the
latter stages of carcinogenesis as previously proposed [1].
Methods
All experiments were performed according to UK Home
Office regulations. Induction of Apc loss was initiated by
giving daily injections (i.p.) of β-napthoflavone (80 mg/
kg). Tissues were harvested at the appropriate time point
and processed as previously described [11]. Immunohis-
tochemistry (IHC) was performed on paraffin embedded
tissues fixed in 4% formaldehyde at 4°C for no more than
24 hours prior to processing. The following antibodies
were used for IHC; p53 1:50, MS104 Labvision, β-catenin
1:50, C19220, Transduction Laboratories, cMyc 1:50 sc-
764, Santa Cruz, p21CIP1/WAF1 1:500, Santa Cruz Tech-
nologies, γ H2AX 1:300, JBW 301, Upstate, lysozyme
1:200, A0099 Dako. Grimelius staining was performed as
previously described by Sansom et al. 2004. Apoptosis
and mitotic index were scored from H&E stained sections
as previously described [12] and apoptosis was independ-
ently confirmed by IHC staining with an antibody against
active caspase 3 (1:750; R&D systems data not shown).
Nuclear area was characterised from H&E stained sections
using the AnalySIS (Soft Imaging Systems) software. Prim-
ers for quantitative real-time RT-PCR (QRT-PCR) (listed
in additional file 1) were designed using primer3 to span
intron-exon boundaries wherever possible. QRT-PCR
reactions were performed using a chromo4 real-time
detector (MJ Research) and standard protocols of 60°C
annealing temperature. Triplicate samples from each gen-
otype were amplified in duplicate and the expression lev-
els of the genes of interest were normalised to the
housekeeping control gene β-actin and analysed as previ-
ously described [13]. Affymetrix Gene Arrays were run at
the Cancer Research UK facility at the Paterson Institute
for Cancer Research, UK using MOE430_2 chips and trip-
licate intestinal samples for each genotype 5 days post
induction using Cre recombinase; Cre+Apcfl/flp53+/
+,Cre+Apcfl/flp53-/-, Cre+Apc+/+p53+/+ and Cre+Apc+/+p53-/-.
The array data generated is available from the Affymetrix
MIAMEVICE web page [14].
Results and discussion
P53 expression and regulation following the loss of Apc
Given that we expect to see p53 expression up-regulated
following activation of Wnt signalling, we initially charac-
terised the p53 expression profile in intestines following
the conditional deletion of Apc. We have developed a
robust protocol which utilises the Ah-cre transgene (pos-
sessing an inducible Cyp1a-driven Cre recombinase [15])
in combination with loxP flanked Apc alleles [16] allow-
ing us to conditionally delete Apc in the adult small intes-
tine [11]. We have previously demonstrated that such
conditional deletion of Apc results in rapid nuclear local-
isation of β-catenin, acute activation of Wnt signalling
and perturbed cell death, proliferation, differentiation
and migration [11]. We have also previously performed
affymetrix microarray expression analysis comparing
Cre+Apcfl/flp53+/+ and Cre+Apc+/+p53+/+ intestines [11], and
this data suggested an approximately 1.7 fold up-regula-
tion of p53 expression following the loss of Apc. We have
now verified this finding by both quantitative real-time
RT-PCR (QRT-PCR) (Figure 1) and immunohistochemis-
try (IHC) (Figure 1). IHC analysis demonstrated that ele-
vated p53 protein occurred only in a discrete set of cells
towards the leading edge, but still within, the aberrant
structure seen following the loss of Apc (Figure 1) and was
not global as was initially expected. Nuclear p53 protein
is not seen within the intestinal epithelium of inducedPage 2 of 9
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2). Thus we are able to exclude the possibility that p53
activation is occurring as a consequence of DNA breaks
transiently generated during Cre mediated recombination
(recombination occurs around LoxP flanked stop cassette
upstream of the LacZ allele). It is pertinent to note that
widespread nuclear β-catenin and c-Myc occurs following
Apc loss (Figure 2c+e) resulting in activation of Wnt target
genes throughout the aberrant structure [11]. The
restricted pattern p53 expression suggests that p53 is not
a global Wnt target gene, or indeed a global c-Myc target
gene, but is deregulated as a consequence of Apc loss in
conjunction with other factors.
Characterisation of p53 deficient Apc deficient intestines
In order to assess the importance of p53 status upon the
early consequences of Apc loss we generated p53 null
mice possessing the Ah-cre transgene and loxP flanked
Apc alleles (designated cre+Apcfl/flp53-/- mice) and condi-
tionally deleted Apc in a p53 deficient environment.
Characterisation of induced cre+Apcfl/flp53-/- mice demon-
strated that the additional loss of p53 in the context of Apc
deficiency did not alter the gross phenotype observed fol-
lowing the loss of Apc (Figure 2).
Induced cre+Apcfl/flp53-/- mice displayed an aberrant crypt-
villus architecture possessing an expanded area of mor-
phologically atypical "crypt-like" cells evident on hema-
toxylin-and-eosin-stained material (Figure 2a+b), in a
manner indistinguishable from Apc loss alone. Rapid
nuclear localisation of β-catenin also occurred in the aber-
rant areas in both genotypes (Figure 2c+d) and the time
scale for loss of differentiation status of enteroendocrine
cells (assessed by Grimelius staining) and Paneth and
goblet cell mislocalisation (assessed using anti-Lysozyme
IHC and alcian blue staining respectively) was identical in
both genotypes (Figure 2g–j).
Apc loss (in induced cre+Apcfl/flp53+/+ mice) is known to
result in an increase in nuclear area primarily in the cells
towards the leading edge of the aberrant structure [17].
The precise mechanisms and relevance of this finding is
currently not known, but given that up-regulation of p53
occurs within this area, we quantified nuclear area in
cre+Apcfl/flp53-/- samples to determine if p53 played any
role in this phenotype. Several lines of evidence suggest
such a role for p53. For example, p53-dependent G1/S
arrest or G2/M arrest are mechanisms employed to pre-
vent genomically unstable cells progressing [18-21]. Fur-
thermore, p53 is up-regulated in response to DNA
damage and other stimuli that can result in aneuploidy,
with p53-deficient cells failing to arrest and developing
centrosome and spindle dysfunction and ultimately aneu-
ploidy [22,23]. Thus it might be expected that p53 defi-
ciency within our system might result in elevated levels of
nuclear atypia. However, no difference was observed in
nuclear area within the leading edge of aberrant morphol-
ogy between induced cre+Apcfl/flp53+/+ and cre+Apcfl/flp53-/-
intestines (Figure 2q), and this phenomenon is therefore
independent of p53 status. Furthermore, IHC analysis
demonstrated continued up-regulation of the p53-
dependent target gene p21CIP1/WAF1 in the absence of
p53 (Figure 2k+l), which is considered to act as a marker
of polyploidy [24].
Given that p53 is a key gene in signalling DNA damage
induced apoptosis and cell cycle arrest in the murine
small intestine, we also assessed whether the apoptosis
that is induced following Apc loss was dependent on p53.
Characterisation of p53 expression levels in induced re+Apcfl/flp53+/+ intestinal samples.Figure 1
Characterisation of p53 expression levels in induced 
Cre+Apcfl/flp53+/+ intestinal samples. a) p53 IHC was per-
formed 4 days post Apc loss and shows that p53 is only up-
regulated in a subset of cells, towards the leading edge but 
within the aberrant structure seen following Apc loss. b) 
QRT-PCR expression analysis of intestinal samples 4 days 
post Apc loss (ApcFlox) confirms that p53 transcript is up-
regulated approximately 2 fold.
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that apoptosis induced by Apc loss is dependent on the
proto-oncogene c-Myc [25] and recent publications high-
lighting the importance of oncogenic activation of DNA
checkpoints at the earliest stages of tumourigenesis
[26,27]. Importantly the levels of apoptosis were not
affected by p53 deficiency (Figure 2p), proving that p53 is
not required for the apoptotic response seen in this set-
ting. Furthermore, there was no significant difference in
the mitotic index between induced cre+Apcfl/flp53+/+ and
cre+Apcfl/flp53-/- intestines (Figure 2p) and we believe that
p53 is not required for the increase in mitotic index seen
following Apc loss. That said induced cre+Apcfl/flp53-/-
intestines were significantly elevated compared to wild
type while induced cre+Apcfl/flp53+/+ intestines were not
(Figure 2p). Therefore, there is a trend based solely on the
mean levels of mitosis following induction, which sug-
gests p53 may act to repress mitosis following Apc loss.
Phenotypic characterisation of induced Cre+Apcfl/flp53-/- and Cre+Apcfl/flp53+/+ intestinal samples.Figure 2
Phenotypic characterisation of induced Cre+Apcfl/flp53-/- and Cre+Apcfl/flp53+/+ intestinal samples. The top panel 
represents induced Cre+Apcfl/flp53+/+ intestinal samples, while the bottom panel represents induced Cre+Apcfl/flp53-/- intestinal 
samples. a+b) H&E staining displays no ascertainable difference between (a) the induced Cre+Apcfl/flp53+/+ and (b) the induced 
Cre+Apcfl/flp53-/-. c+d) β-catenin IHC and e+f) cMyc IHC display nuclear staining throughout the aberrant structure in both sam-
ple types. g+h) IHC detecting lysozyme positivity shows that paneth cell mis-localisation occurs in an identical manner in both 
genotypes with complete mis-localisation occurring 6 days after induction. i+j) Grimelius staining shows no ascertainable differ-
ence between the two induced genotypes. k+l) p21CIP1/WAF1 IHC displays a band of positively stained cells displaying an 
enlarged nuclear area and the leading edge of aberrancy adjacent to phenotypically normal cells in both induced genotypes. 
m+n) γ H2AX IHC shows no difference between the 2 genotypes. p) Apoptotic and mitotic crypt indices show no differences 
between the induced Cre+Apcfl/flp53-/- and Cre+Apcfl/flp53+/+ intestinal samples (assessed using t-test), asterisks signify a signifi-
cant difference (p < 0.05) compared to the control levels. q) Characterisation of the nuclear area at the crypt-villus (or aber-
rant-normal) junction show both the induced Cre+Apcfl/flp53-/- and Cre+Apcfl/flp53+/+ samples display an increase in the number 
of larger nuclei compared to control Cre+Apc+/+p53-/- and Cre+Apc+/+p53+/+ samples. Yet again no differences between the 
induced Cre+Apcfl/flp53-/- and Cre+Apcfl/flp53+/+ samples could be identified.
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BMC Cancer 2008, 8:162 http://www.biomedcentral.com/1471-2407/8/162However, we consider the evidence to support such a p53
dependent role to be rather weak.
We also assessed γ-H2AX levels to investigate the levels of
DNA damage occurring in both genotypes. γ-H2AX foci
have been shown to localize at double-strand DNA breaks
[28] and we show here that expression levels of γ-H2AX
are up-regulated (approximately 3 fold) following Apc
loss (Figure 3) and widespread γ-H2AX staining occurs
throughout the aberrant structure (Figure 2m) which is
not seen in induced cre+Apc+/+P53+/+ control samples
(data not shown). This widespread γ-H2AX staining is
seen at a similar level in the absence of p53 (Figure 2n and
QRT-PCR analysis confirms that expression levels are not
altered in the absence of p53 (Figure 3). Thus, loss of Apc
results in the rapid elevation of γ-H2AX levels, consistent
with its role as a marker of increased DNA damage,
another hallmark of neoplasia which we observe to be
independent of p53 status.
Characterisation of Wnt signalling in a p53 deficient Apc 
deficient intestine
We next wished to closely address whether p53 loss was
subtly affecting Wnt signalling and therefore employed
affymetrix micro-array analysis to compare the transcrip-
tome profiles of induced Cre+Apcfl/flp53-/- and induced
Cre+Apcfl/flp53+/+ intestines compared to control Cre+Apc+/
+p53+/+.
Array date was screened (using a cut-off of at least one p
value for each probe ID <0.2), normalised (global geo-
metric mean) using the MaxD/View-Program and ana-
lysed using the SAM-Program [29,30]. Pair-wise
comparison between induced Cre+Apcfl/flp53-/- and control
induced Cre+Apc+/+p53+/+ samples identified a total of 78
significantly altered probe ID's using a stringent 2% false
discovery rate (FDR) (additional file 3). Of these, 53
(Table 1) were not identified in SAM outputs comparing
induced Cre+Apcfl/flp53+/+ to induced control Cre+Apc+/
+p53+/+ samples or induced Cre+Apc+/+p53-/- to induced
control Cre+Apc+/+p53+/+ samples. These gene changes are
therefore classified as statistically altered (using a 2% FDR
cut-off) specifically following the combined loss of both
p53 and Apc. It should be noted that a proportion of these
genes may display an altered expression profile in either
induced Cre+Apcfl/flp53+/+ or induced Cre+Apc+/+p53-/-, but
they are not identified as statistically altered by SAM anal-
ysis using the stringent cut-off level of 2%FRD, but are
only identified using less stringent cut-off levels. Two of
these genes, Lect2 and Axin2, are known Wnt target genes,
the expression profiles of which were confirmed across
the genotypes using Q-RTPCR (Figure 3). Indeed for both
genes, although they are deregulated following Apc loss,
we observed heightened induction in the combined
absence of Apc and p53. This is consistent with loss of a
feedback mechanism in the absence of p53, or indeed the
induction of an alternate feedback mechanism, as both
Axin2 and Lect2 are known Wnt repressors as well as Wnt
targets [31,32].
We also employed a candidate gene approach, looking at
the expression levels of a number of confirmed Wnt target
genes to address whether p53 status affects the amplitude
of Wnt signalling following Apc loss. This analysis used Q-
RTPCR (Figure 3) to show that a subset of Wnt target
genes (CyclinD2, Mash2, Lef1, CD44) are also expressed
more highly following Wnt signalling activation in the
absence of p53. This is again consistent with a loss of a
p53-dependent regulatory feedback loop. Notably, from
this analysis it is also clear that some but not all aspects of
Wnt signalling are affected by p53 status. For example,
Tcf4 (data not shown), Frizzled7 and c-Myc were analysed
by Q-RTPCR and showed no differences in expression pat-
terns in the additional absence of p53.
We also employed the candidate gene approach to look at
the expression of genes proposed to be involved in the
p53 dependent regulatory feedback loops using Q-RTPCR
i.e. p19arf, Mdm2, Siah1a, Saih1b and Tcf4. The only note-
worthy difference detected was reduced levels of Siah1b
expression in the induced Cre+Apcfl/flp53-/- compared to
the induced Cre+Apcfl/flp53+/+ samples (Figure 3) (p < 0.05
T-test using ΔCT values). Siah1 is a known p53 target gene
that appears to be significantly up-regulated (~3 fold up-
regulated compared to control, p < 0.05 using T-test of
ΔCT values) in induced Cre+Apcfl/flp53+/+ intestinal sam-
ples. Siah1 has previously been shown to interact with
APC to promote the degradation of β-catenin, independ-
ent of GSK3b phosphorylation of β-catenin [6], and its
up-regulation following Apc loss potentially represents a
regulatory feedback mechanism. The reduced levels of
expression of Siah1b in Cre+Apcfl/flp53-/-compared to
Cre+Apcfl/flp53+/+ samples confirm p53-dependent expres-
sion. However, Siah1b expression is still up-regulated
(approximately 2 fold) in Cre+Apcfl/flp53-/- samples com-
pared to control Cre+Apc+/+p53+/+ samples (Figure 3), sug-
gesting that p53 independent mechanisms also operate to
regulate Siah1b expression levels following the loss of Apc.
Furthermore, the proposed mechanism of Siah1b regula-
tion requires an interaction with Apc. However, in our
experimental system we have also removed Apc, rendering
the proposed Siah1b feedback mechanism redundant in
this instance.
Finally, we also employed Sam analysis to compare the
profiles of induced Cre+Apcfl/flp53-/- and induced Cre+Apcfl/
flp53+/+ intestines. This identified a number of potential
differences using an FDR of 15%, (no differences could be
identified using a lower FDR) and we subsequently
attempted to confirm the expression patterns for aPage 5 of 9
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QRT-PCR expression analysis of candidate genes.Figure 3
QRT-PCR expression analysis of candidate genes. QRT-PCR expression analysis was on intestinal samples from 
Cre+Apcfl/flp53+/+ (ApcFlox),Cre+Apcfl/flp53-/- (Double), Cre+Apc+/+p53+/+ (WT) and Cre+Apc+/+p53-/- (P53null) intestinal samples, 
4 days post induction. The histogram shows the fold change of expression levels in experimental samples relative to control 
samples, while error bars show the standard deviation of ΔCT values obtained for the replicates of each sample type. Asterisks 
denote a significant difference between the experimental and control ΔCT values, as assessed using the T-test p < 0.05.
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Table 1: Changes unique tox double Cre+Apcfl/flp53-/- samples.
Probe set ID Gene Symbol Gene Title Fold Change in Apcfl/fl p53-/- v WT
1418368_at Retnlb resistin like beta 0.002
1422422_at Defcr4 defensin related cryptdin 4 27.73
1425221_at Agr3 anterior gradient homolog 3 (Xenopus laevis) 27.20
1460582_x_at a Nonagouti 17.82
1421837_at Rps18 ribosomal protein S18 8.12
1422934_x_at Defcr-rs7 defensin related cryptdin, related sequence 7 30.91
452183_a_at Gtl2 GTL2, imprinted maternally expressed untranslated mRNA 25.82
1421838_at Rps18 ribosomal protein S18 8.60
1459443_at Kcnq1 Potassium voltage-gated channel, subfamily Q, member 1 9.67
1447260_at ENSMUSG000000734 ENSMUSG00000073403 12.11
1426340_at Slc1a3 solute carrier family 1 (glial high affinity glutamate transporter), 
member 3
13.83
1455274_at a Nonagouti 19.31
1422071_at Lgals6 lectin, galactose binding, soluble 6 11.52
1420748_a_at Adat1 adenosine deaminase, tRNA-specific 1 4.33
1423017_a_at Il1rn interleukin 1 receptor antagonist 12.54
1449492_a_at Lect2 leukocyte cell-derived chemotaxin 2 43.73
1443536_at Slc7a11 solute carrier family 7 (cationic amino acid transporter, y+ 
system), member 11
13.16
1446728_at D3Ertd797e DNA segment, Chr 3, ERATO Doi 797, expressed 2.39
1459779_s_at Setd8 SET domain containing (lysine methyltransferase) 8 6.92
1421257_at Pigb phosphatidylinositol glycan anchor biosynthesis, class B 11.65
1446730_at C79267 Expressed sequence C79267 10.65
1459834_x_at --- --- 4.64
1460604_at Cybrd1 cytochrome b reductase 1 22.55
1427580_a_at Rian RNA imprinted and accumulated in nucleus 9.54
1418708_at Apoc4 apolipoprotein C-IV 19.03
1422597_at Mmp15 matrix metallopeptidase 15 10.55
1434734_at E130016E03Rik RIKEN cDNA E130016E03 gene 9.11
1441594_at --- --- 5.86
1441624_at Sorbs2 sorbin and SH3 domain containing 2 3.78
1434028_at Arnt2 aryl hydrocarbon receptor nuclear translocator 2 11.43
1427967_at Srgap2 SLIT-ROBO Rho GTPase activating protein 2 9.36
1434497_at 4933431E20Rik RIKEN cDNA 4933431E20 gene 7.73
1444538_at Snd1 Staphylococcal nuclease and tudor domain containing 1 8.68
1457636_x_at --- --- 5.12
1436845_at Axin2 axin2 4.58
1457262_at 2610207I05Rik RIKEN cDNA 2610207I05 gene 5.35
1431031_at Arid4b AT rich interactive domain 4B (Rbp1 like) 3.55
1439380_x_at Gtl2 GTL2, imprinted maternally expressed untranslated mRNA 7.69
1417520_at Nfe2l3 nuclear factor, erythroid derived 2, like 3 6.40
1446376_at Rps6kb1 ribosomal protein S6 kinase, polypeptide 1 5.88
1422882_at Sypl synaptophysin-like protein 4.91
1444498_at --- --- 7.23
1438258_at Vldlr very low density lipoprotein receptor 6.85
1422954_at Zfp60 zinc finger protein 60 3.25
1425986_a_at Dcun1d DCUN1D1 DCN1, defective in cullin neddylation 1, domain 
containing 1 (S. cerevisiae)
2.49
1430458_at Supt6h suppressor of Ty 6 homolog (S. cerevisiae) 3.17
1434734_at E130016E03Rik RIKEN cDNA E130016E03 gene 9.11
1435082_at Syp1 synaptophysin-like protein 5.30
1437065_at Zbtb20 zinc finger and BTB domain containing 20 12.39
1441487_at Trim2 tripartite motif protein 2 5.68
1443628_at --- --- 9.06
1447386_at Usp2 Ubiquitin specific peptidase 8 2.94
1455327_at Senp2 SUMO/sentrin specific peptidase 2 4.36
The transcripts shown are significantly altered (2% FDR SAM analysis) exclusively in induced Cre+Apcfl/fl p53-/- samples compared to induced control 
Cre+Apc+/+ p53+/+ samples (not observed in either Cre+Apcfl/fl p53+/+ or Cre+Apc+/+ p53-/- compared to control using 2%FDR).
BMC Cancer 2008, 8:162 http://www.biomedcentral.com/1471-2407/8/162number of genes that the array data suggested were
Cre+Apcfl/flp53-/- specific alterations. Of 8 transcripts ana-
lysed, two (Slc39a14 and Hapb2) proved to be signifi-
cantly different between induced Cre+Apcfl/flp53-/- and
induced Cre+Apcfl/flp53+/+ intestines (Figure 3). The signif-
icance in the alteration of these 2 transcripts is currently
unknown.
Conclusion
The restricted pattern of p53 up-regulation seen following
the loss of Apc (Figure 1) was contrary to expectation,
given active Wnt signalling is reported to promote p53
transcription [33]. Our data therefore argues that p53 is
not a direct Wnt target, at least in the context analysed
here. Notably the upregulation of p53 is associated with a
zone of cells showing nuclear atypia, however we show
that the development of this atypia is independent of p53,
and indeed p21CIP1/WAF1 levels remain high within
these cells. Furthermore, our data show that all the imme-
diate phenotypes we observe following Apc loss are
unchanged by additional p53 deficiency. With respect to
apoptosis, p53 status may be rendered redundant through
Wnt-mediated induction of WIP1, a protein which has
previously been shown to suppress p53-dependent apop-
tosis in the intestine [34].
Despite the absence of phenotypic change, deficiency of
p53 did modulate the transcriptome. Most significantly,
we observed deregulation of a number of key Wnt path-
way components and targets. These observations are con-
sistent with a feedback role for p53 in the Wnt pathway;
however, this activity is insufficient to modulate the
immediate phenotype of Apc loss, possibly because the
feedback mechanisms become swamped in the absence of
Apc. Overall, our data suggests p53 status has little impact
upon the initiating stages of intestinal disease, but they do
provide support for physiological Wnt pathway regula-
tion, albeit overwhelmed in this setting. The possibility
remains that p53 status truly regulates Wnt pathway activ-
ity in settings of lower levels of Wnt signalling. The lack of
a potent role for p53 immediately following Apc loss also
provides a ready explanation for the association of p53
mutation with only the later stages of colorectal disease
[1].
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